359 related articles for article (PubMed ID: 24374844)
21. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
Yan XC; Sun LS; Dong ZW; You Z; Dong Q
Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
[TBL] [Abstract][Full Text] [Related]
22. Frequency of BRAF V600E mutation in a group of Thai patients with ameloblastomas.
Lapthanasupkul P; Laosuk T; Ruangvejvorachai P; Aittiwarapoj A; Kitkumthorn N
Oral Surg Oral Med Oral Pathol Oral Radiol; 2021 Nov; 132(5):e180-e185. PubMed ID: 32665205
[TBL] [Abstract][Full Text] [Related]
23. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
[No Abstract] [Full Text] [Related]
24. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
[TBL] [Abstract][Full Text] [Related]
25. High frequency of BRAF V600E mutation in Iranian population ameloblastomas.
Derakhshan S; Aminishakib P; Karimi A; Saffar H; Abdollahi A; Mohammadpour H; Kharazi Fard MJ; Memarha A
Med Oral Patol Oral Cir Bucal; 2020 Jul; 25(4):e502-e507. PubMed ID: 32388526
[TBL] [Abstract][Full Text] [Related]
26. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.
Ohashi K; Sequist LV; Arcila ME; Moran T; Chmielecki J; Lin YL; Pan Y; Wang L; de Stanchina E; Shien K; Aoe K; Toyooka S; Kiura K; Fernandez-Cuesta L; Fidias P; Yang JC; Miller VA; Riely GJ; Kris MG; Engelman JA; Vnencak-Jones CL; Dias-Santagata D; Ladanyi M; Pao W
Proc Natl Acad Sci U S A; 2012 Jul; 109(31):E2127-33. PubMed ID: 22773810
[TBL] [Abstract][Full Text] [Related]
27. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
28. Advancements in MAPK signaling pathways and MAPK-targeted therapies for ameloblastoma: A review.
You Z; Liu SP; Du J; Wu YH; Zhang SZ
J Oral Pathol Med; 2019 Mar; 48(3):201-205. PubMed ID: 30489659
[TBL] [Abstract][Full Text] [Related]
29. High prevalence of BRAF V600E mutations in Korean patients with ameloblastoma: Clinicopathological significance and correlation with epithelial-mesenchymal transition.
Oh KY; Cho SD; Yoon HJ; Lee JI; Ahn SH; Hong SD
J Oral Pathol Med; 2019 May; 48(5):413-420. PubMed ID: 30889301
[TBL] [Abstract][Full Text] [Related]
30. Molecular pathogenesis of ameloblastoma.
Marín-Márquez C; Kirby J; Hunter KD
J Oral Pathol Med; 2024 May; 53(5):277-293. PubMed ID: 38664938
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study.
Shinozaki E; Yoshino T; Yamazaki K; Muro K; Yamaguchi K; Nishina T; Yuki S; Shitara K; Bando H; Mimaki S; Nakai C; Matsushima K; Suzuki Y; Akagi K; Yamanaka T; Nomura S; Fujii S; Esumi H; Sugiyama M; Nishida N; Mizokami M; Koh Y; Abe Y; Ohtsu A; Tsuchihara K
Br J Cancer; 2017 Nov; 117(10):1450-1458. PubMed ID: 28972961
[TBL] [Abstract][Full Text] [Related]
32. Association of MDM2 Overexpression in Ameloblastomas with
Tosios KI; Kalogirou EM; Koutlas IG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396916
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant BRAF-targeted therapy for ameloblastoma of the mandible: an organ preservation approach.
Grynberg S; Vered M; Shapira-Frommer R; Asher N; Ben-Betzalel G; Stoff R; Steinberg Y; Amariglio N; Greenberg G; Barshack I; Toren A; Yahalom R; Schachter J; Rechavi G; Hirschhorn A; Abebe Campino G
J Natl Cancer Inst; 2024 Apr; 116(4):539-546. PubMed ID: 37966914
[TBL] [Abstract][Full Text] [Related]
34. Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma.
Kondo S; Ota A; Ono T; Karnan S; Wahiduzzaman M; Hyodo T; Lutfur Rahman M; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
Cancer Med; 2020 Apr; 9(8):2904-2917. PubMed ID: 32096304
[TBL] [Abstract][Full Text] [Related]
35. Adenoid Ameloblastoma with BRAF p.V600E Mutation Revealing Ameloblastomatous Origin: A First Case Report.
Noda Y; Sawada S; Sakagami T; Kojima Y; Higasa K; Tsuta K
Head Neck Pathol; 2023 Sep; 17(3):788-792. PubMed ID: 37093491
[TBL] [Abstract][Full Text] [Related]
36. The importance of BRAF-V600E mutation to ameloblastoma metabolism.
Duarte-Andrade FF; Silva AMB; Vitório JG; Canuto GAB; Costa SFS; Diniz MG; Fernandes AP; de Toledo JS; André LC; Gomes CC; Gomez RS; Fonseca FP
J Oral Pathol Med; 2019 Apr; 48(4):307-314. PubMed ID: 30739334
[TBL] [Abstract][Full Text] [Related]
37. BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature.
Ebeling M; Scheurer M; Sakkas A; Pietzka S; Schramm A; Wilde F
Med Oncol; 2023 Apr; 40(6):163. PubMed ID: 37115331
[TBL] [Abstract][Full Text] [Related]
38. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
[TBL] [Abstract][Full Text] [Related]
39. [BRAF V600E expression in ameloblastomas, ameloblastic carcinomas and cysts].
Pei J; Zhang L; Jia YX; Chen WH
Shanghai Kou Qiang Yi Xue; 2023 Dec; 32(6):630-634. PubMed ID: 38494972
[TBL] [Abstract][Full Text] [Related]
40. The BRAF p.V600E mutation is a common event in ameloblastomas but is absent in odontogenic keratocysts.
Zhang R; Yang Q; Qu J; Hong Y; Liu P; Li T
Oral Surg Oral Med Oral Pathol Oral Radiol; 2020 Mar; 129(3):229-235. PubMed ID: 31987674
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]